The Biossays homocysteine and lipid assays demonstrated satisfactory analytical performance, and among hospital-based hypertensive individuals in East Shenzhen, the estimated 10-year cardiovascular disease risk differed across ages but not between sexes, while hyperhomocysteinemia and lipid abnormalities were frequently observed.
The Biossays homocysteine, total cholesterol, triglyceride, LDL-C, and HDL-C assays showed satisfactory analytical performance.
Estimated 10-year cardiovascular disease risk by the China-PAR model differed across age groups but not between sexes in the hypertension cohort.
Hyperhomocysteinemia was highly prevalent among individuals with hypertension, depending on the cutoff used.
Lipid abnormalities were common in the hypertension cohort.
Lipid abnormalities were also common in the hospital laboratory population in 2024.
The study combined assay validation, a prospective cross-sectional hypertension cohort, and a retrospective laboratory database analysis in a single hospital-based setting.
This study tested a set of laboratory kits (from Biossays) that measure homocysteine and blood fats (total cholesterol, triglycerides, LDL and HDL cholesterol). The tests met standard quality criteria for precision, accuracy, sensitivity, and linearity, suggesting they can be reliably used in clinical practice. The researchers also looked at 400 people with hypertension at a hospital in East Shenzhen, China, and estimated their 10-year risk of cardiovascular disease using a Chinese risk model (China-PAR). Risk differed across age groups but not between men and women. High homocysteine was very common: about 85.5% had levels of at least 10 μmol/L, and about 33.8% had levels of at least 15 μmol/L. About 68% had at least one abnormal blood fat measure. In a separate review of 55,575 people with lipid tests at the same hospital in 2024, about 62% had at least one abnormal lipid value. This research suggests that high homocysteine and lipid abnormalities are common in hospital-based populations like this one, and that checking them may help with cardiovascular risk assessment and prevention. Because the data come from a single hospital, the findings may not apply to the general population.
Chen L, Zhang B, Xie G, Chen C, Shi M, Fan R, et al.. (2026). China-PAR-based cardiovascular risk assessment in East Shenzhen using Biossays homocysteine and lipid assays: A prospective cross-sectional and retrospective study.. The Journal of international medical research. https://doi.org/10.1177/03000605261500362